|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 45/06 | |
| A61P 29/00 | |||
| A61K 31/4418 | |||
| A61K 31/517 |
| (11) | Number of the document | 2178562 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08775119.4 |
| Date of filing the European patent application | 2008-07-16 | |
| (97) | Date of publication of the European application | 2010-04-28 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2008/059296 |
| Date | 2008-07-16 |
| (87) | Number | WO 2009/010529 |
| Date | 2009-01-22 |
| (30) | Number | Date | Country code |
| 07112679 | 2007-07-18 | EP |
| (72) |
FOX, Alyson, GB
NASH, Mark, GB
SOHAL, Bindi, GB
LILLEY, Elliot, GB
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |